#METABOLOMICS WORKBENCH hormel101_20180409_153445 DATATRACK_ID:1360 STUDY_ID:ST000947 ANALYSIS_ID:AN001555 PROJECT_ID:PR000652
VERSION             	1
CREATED_ON             	April 10, 2018, 10:17 pm
#PROJECT
PR:PROJECT_TITLE                 	Mayo Pilot and Feasibility: Mechanisms for Insulin Resistance in Polycystic
PR:PROJECT_TITLE                 	Ovary Syndrome
PR:PROJECT_SUMMARY               	Polycystic Ovary Syndrome (PCOS), a condition of androgen excess, infrequent
PR:PROJECT_SUMMARY               	ovulation, and insulin resistance is the most common endocrine disorder among
PR:PROJECT_SUMMARY               	premenopausal women. Little is known about the exact mechanisms of insulin
PR:PROJECT_SUMMARY               	resistance in PCOS and how metformin can improve insulin sensitivity, increase
PR:PROJECT_SUMMARY               	the frequency of ovulation and lower androgens in PCOS. Preliminary data from
PR:PROJECT_SUMMARY               	metabolomic analyses of amino acids demonstrate increased concentrations of
PR:PROJECT_SUMMARY               	lysine and its metabolite, α-aminoadipic acid (AAA), in PCOS versus obese
PR:PROJECT_SUMMARY               	controls. Interestingly, greater AAA concentrations predicted the development of
PR:PROJECT_SUMMARY               	type 2 diabetes in the Framingham epidemiologic cohort, experimentally lowers
PR:PROJECT_SUMMARY               	glucose in animal models and increases insulin secretion in vitro. To date, the
PR:PROJECT_SUMMARY               	mechanism for increased circulating concentrations of lysine and AAA in
PR:PROJECT_SUMMARY               	insulin-resistant individuals is not known. Building upon these findings, we
PR:PROJECT_SUMMARY               	have initiated a project to simultaneously study lysine and AAA kinetics for the
PR:PROJECT_SUMMARY               	first time in insulin-resistant individuals using stable isotope tracer
PR:PROJECT_SUMMARY               	methodology. We will evaluate: 1) whether lysine and AAA kinetics are altered in
PR:PROJECT_SUMMARY               	PCOS versus healthy controls; 2) the effect of hyperinsulinemia on lysine and
PR:PROJECT_SUMMARY               	AAA kinetics in PCOS versus controls; 3) whether treatment to improve insulin
PR:PROJECT_SUMMARY               	sensitivity changes lysine and AAA kinetics in PCOS. The long-term goal is to
PR:PROJECT_SUMMARY               	target pathways for the treatment of PCOS and the prevention of type 2 diabetes
PR:PROJECT_SUMMARY               	in PCOS and other insulin-resistant individuals at greater risk for type 2
PR:PROJECT_SUMMARY               	diabetes.
PR:INSTITUTE                     	Mayo Clinic
PR:LAST_NAME                     	Chang
PR:FIRST_NAME                    	Alice
PR:ADDRESS                       	200 First St. SW, Rochester, Minnesota, 55905, USA
PR:EMAIL                         	Chang.Alice1@mayo.edu
PR:PHONE                         	507-286-0505
#STUDY
ST:STUDY_TITLE                   	Mechanisms for Insulin Resistance in Polycystic Ovary Syndrome: aminoadipic
ST:STUDY_TITLE                   	acid, lysine concentrations, and enrichment (part I)
ST:STUDY_SUMMARY                 	"To determine whether altered lysine and α-aminoadipic acid (AAA) kinetics
ST:STUDY_SUMMARY                 	explain previous observations of increased lysine and AAA concentrations in PCOS
ST:STUDY_SUMMARY                 	compared to controls, as measured by baseline lysine and AAA flux in PCOS versus
ST:STUDY_SUMMARY                 	healthy controls using [α-15N]-lysine and [13C]-AAA stable isotope tracers as
ST:STUDY_SUMMARY                 	well as by comparing the conversion of [α-15N]-lysine to [15N]-AAA. To evaluate
ST:STUDY_SUMMARY                 	how hyperinsulinemia affects lysine and AAA kinetics. Changes in lysine and AAA
ST:STUDY_SUMMARY                 	flux during a hyperinsulinemic-euglycemic clamp will be evaluated in healthy
ST:STUDY_SUMMARY                 	controls and compared to the baseline changes in lysine and AAA flux in PCOS."
ST:INSTITUTE                     	Mayo Clinic
ST:LAST_NAME                     	Chang
ST:FIRST_NAME                    	Al
ST:ADDRESS                       	200 First St. SW, Rochester, Minnesota, 55905, USA
ST:EMAIL                         	Chang.Alice1@mayo.edu
ST:PHONE                         	507-286-0505
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-1	Time point:baseline | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-2	Time point:-60 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-3	Time point:-45 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-4	Time point:-30 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-5	Time point:-15 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-6	Time point:60 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-7	Time point:120 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-8	Time point:135 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-9	Time point:150 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-10	Time point:165 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	7744	ms6032-11	Time point:180 | Group:control	Date of study=12/20/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-1	Time point:baseline | Group:PCOS	Date of study=11/14/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-2	Time point:-60 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-3	Time point:-45 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-4	Time point:-30 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-5	Time point:-15 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-6	Time point:60 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-7	Time point:120 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-8	Time point:135 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-9	Time point:150 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-10	Time point:165 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6039-11	Time point:180 | Group:PCOS	Date of study=11/15/2015
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-1	Time point:baseline | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-2	Time point:-60 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-3	Time point:-45 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-4	Time point:-30 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-5	Time point:-15 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-6	Time point:60 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-7	Time point:120 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-8	Time point:135 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-9	Time point:150 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-10	Time point:165 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	3437	ms6087-11	Time point:180 | Group:PCOS	Date of study=2/20/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-1	Time point:baseline | Group:control	Date of study=3/22/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-2	Time point:-60 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-3	Time point:-45 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-4	Time point:-30 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-5	Time point:-15 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-6	Time point:60 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-7	Time point:120 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-8	Time point:135 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-9	Time point:150 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-10	Time point:165 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	1002	ms6184-11	Time point:180 | Group:control	Date of study=3/23/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-1	Time point:baseline | Group:control	Date of study=5/11/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-2	Time point:-60 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-3	Time point:-45 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-4	Time point:-30 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-5	Time point:-15 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-6	Time point:60 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-7	Time point:120 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-8	Time point:135 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-9	Time point:150 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-10	Time point:165 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	2850	ms6185-11	Time point:180 | Group:control	Date of study=5/12/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-1	Time point:baseline | Group:PCOS	Date of study=5/3/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-2	Time point:-60 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-3	Time point:-45 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-4	Time point:-30 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-5	Time point:-15 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-6	Time point:60 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-7	Time point:120 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-8	Time point:135 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-9	Time point:150 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-10	Time point:165 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	5908	ms6189-11	Time point:180 | Group:PCOS	Date of study=5/4/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-1	Time point:baseline | Group:control	Date of study=3/282016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-2	Time point:-60 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-3	Time point:-45 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-4	Time point:-30 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-5	Time point:-15 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-6	Time point:60 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-7	Time point:120 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-8	Time point:135 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-9	Time point:150 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-10	Time point:165 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	8404	ms6188-11	Time point:180 | Group:control	Date of study=3/30/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-1	Time point:baseline | Group:control	Date of study=5/26/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-2	Time point:-60 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-3	Time point:-45 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-4	Time point:-30 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-5	Time point:-15 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-6	Time point:60 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-7	Time point:120 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-8	Time point:135 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-9	Time point:150 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-10	Time point:165 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6842	ms6243-11	Time point:180 | Group:control	Date of study=5/27/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-1	Time point:baseline | Group:PCOS	Date of study=1/28/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-2	Time point:-60 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-3	Time point:-45 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-4	Time point:-30 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-5	Time point:-15 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-6	Time point:60 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-7	Time point:120 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-8	Time point:135 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-9	Time point:150 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-10	Time point:165 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	6722	ms6275-11	Time point:180 | Group:PCOS	Date of study=11/6/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-1	Time point:baseline | Group:control	Date of study=3/6/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-2	Time point:-60 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-3	Time point:-45 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-4	Time point:-30 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-5	Time point:-15 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-6	Time point:60 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-7	Time point:120 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-8	Time point:135 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-9	Time point:150 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-10	Time point:165 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	9631	ms6183-11	Time point:180 | Group:control	Date of study=3/7/2016
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-1	Time point:baseline | Group:PCOS	Date of study=3/10/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-2	Time point:-60 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-3	Time point:-45 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-4	Time point:-30 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-5	Time point:-15 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-6	Time point:60 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-7	Time point:120 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-8	Time point:135 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-9	Time point:150 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-10	Time point:165 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	7725	ms6186-11	Time point:180 | Group:PCOS	Date of study=3/11/2015
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-1	Time point:baseline | Group:PCOS	Date of study=4/21/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-2	Time point:-60 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-3	Time point:-45 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-4	Time point:-30 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-5	Time point:-15 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-6	Time point:60 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-7	Time point:120 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-8	Time point:135 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-9	Time point:150 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-10	Time point:165 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	4620	ms6187-11	Time point:180 | Group:PCOS	Date of study=4/22/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-1	Time point:baseline | Group:PCOS	Date of study=1/12/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-2	Time point:-60 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-3	Time point:-45 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-4	Time point:-30 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-5	Time point:-15 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-6	Time point:60 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-7	Time point:120 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-8	Time point:135 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-9	Time point:150 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-10	Time point:165 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	3635	ms6100-11	Time point:180 | Group:PCOS	Date of study=1/13/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-1	Time point:baseline | Group:control	Date of study=2/16/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-2	Time point:-60 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-3	Time point:-45 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-4	Time point:-30 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-5	Time point:-15 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-6	Time point:60 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-7	Time point:120 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-8	Time point:135 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-9	Time point:150 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-10	Time point:165 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	6737	ms6102-11	Time point:180 | Group:control	Date of study=2/17/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-1	Time point:baseline | Group:control	Date of study=12/13/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-2	Time point:-60 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-3	Time point:-45 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-4	Time point:-30 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-5	Time point:-15 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-6	Time point:60 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-7	Time point:120 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-8	Time point:135 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-9	Time point:150 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-10	Time point:165 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5551	ms6182-11	Time point:180 | Group:control	Date of study=12/21/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-1	Time point:baseline | Group:control	Date of study=1/23/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-2	Time point:-60 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-3	Time point:-45 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-4	Time point:-30 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-5	Time point:-15 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-6	Time point:60 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-7	Time point:120 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-8	Time point:135 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-9	Time point:150 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-10	Time point:165 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	5844	ms6034-11	Time point:180 | Group:control	Date of study=1/24/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-1	Time point:baseline | Group:PCOS	Date of study=11/16/2015
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-2	Time point:-60 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-3	Time point:-45 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-4	Time point:-30 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-5	Time point:-15 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-6	Time point:60 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-7	Time point:120 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-8	Time point:135 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-9	Time point:150 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-10	Time point:165 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6091-11	Time point:180 | Group:PCOS	Date of study=11/17/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-1	Time point:baseline | Group:PCOS	Date of study=2/22/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-2	Time point:-60 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-3	Time point:-45 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-4	Time point:-30 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-5	Time point:-15 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-6	Time point:60 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-7	Time point:120 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-8	Time point:135 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-9	Time point:150 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-10	Time point:165 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	2780	ms6098-11	Time point:180 | Group:PCOS	Date of study=2/23/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-1	Time point:baseline | Group:control	Date of study=1/18/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-2	Time point:-60 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-3	Time point:-45 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-4	Time point:-30 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-5	Time point:-15 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-6	Time point:60 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-7	Time point:120 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-8	Time point:135 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-9	Time point:150 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-10	Time point:165 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8696	ms6036-11	Time point:180 | Group:control	Date of study=1/19/2016
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-1	Time point:baseline | Group:PCOS	Date of study=12/15/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-2	Time point:-60 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-3	Time point:-45 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-4	Time point:-30 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-5	Time point:-15 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-6	Time point:60 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-7	Time point:120 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-8	Time point:135 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-9	Time point:150 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-10	Time point:165 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	8999	ms6042-11	Time point:180 | Group:PCOS	Date of study=12/16/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-1	Time point:baseline | Group:PCOS	Date of study=12/18/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-2	Time point:-60 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-3	Time point:-45 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-4	Time point:-30 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-5	Time point:-15 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-6	Time point:60 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-7	Time point:120 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-8	Time point:135 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-9	Time point:150 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-10	Time point:165 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7182	ms6099-11	Time point:180 | Group:PCOS	Date of study=12/19/2015
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-1	Time point:baseline | Group:control	Date of study=1/25/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-2	Time point:-60 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-3	Time point:-45 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-4	Time point:-30 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-5	Time point:-15 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-6	Time point:60 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-7	Time point:120 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-8	Time point:135 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-9	Time point:150 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-10	Time point:165 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	7534	ms6035-11	Time point:180 | Group:control	Date of study=1/26/2016
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-1	Time point:baseline | Group:PCOS	Date of study=12/1/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-2	Time point:-60 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-3	Time point:-45 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-4	Time point:-30 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-5	Time point:-15 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-6	Time point:60 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-7	Time point:120 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-8	Time point:135 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-9	Time point:150 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-10	Time point:165 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	3463	ms6038-11	Time point:180 | Group:PCOS	Date of study=12/2/2015
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-1	Time point:baseline | Group:PCOS	Date of study=2/18/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-2	Time point:-60 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-3	Time point:-45 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-4	Time point:-30 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-5	Time point:-15 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-6	Time point:60 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-7	Time point:120 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-8	Time point:135 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-9	Time point:150 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-10	Time point:165 | Group:PCOS	Date of study=2/19/2016
SUBJECT_SAMPLE_FACTORS           	6454	ms6101-11	Time point:180 | Group:PCOS	Date of study=2/19/2016
#COLLECTION
CO:COLLECTION_SUMMARY            	We will perform a hyperinsulinemic-euglycemic clamp as previously described
CO:COLLECTION_SUMMARY            	except that in this current proposal we will perform the study for 3 hours.(36)
CO:COLLECTION_SUMMARY            	The goal for this infusion is to assess the effect of hyperinsulinemia on lysine
CO:COLLECTION_SUMMARY            	and AAA kinetics and whether metformin changes the effect of hyperinsulinemia.
CO:COLLECTION_SUMMARY            	We will collect samples every 10 min for glucose. 40% dextrose will be infused
CO:COLLECTION_SUMMARY            	at a variable rate during the clamp to maintain euglycemia.(36) During the last
CO:COLLECTION_SUMMARY            	hour of the clamp, 5 blood samples will be drawn for measurement of stable
CO:COLLECTION_SUMMARY            	isotope tracer enrichment and amino acid concentrations.
CO:SAMPLE_TYPE                   	Blood (plasma)
#TREATMENT
TR:TREATMENT_SUMMARY             	"Ten women with PCOS will receive metformin therapy, and ten women will be
TR:TREATMENT_SUMMARY             	randomized to receive no therapy and undergo the same repeat visits after 3
TR:TREATMENT_SUMMARY             	months. Ten age-matched women without PCOS with a BMI < 25 will be recruited as
TR:TREATMENT_SUMMARY             	the control group for the baseline visit. Aside from criteria that they do not
TR:TREATMENT_SUMMARY             	have PCOS and have a BMI < 25, this control group will have the same inclusion
TR:TREATMENT_SUMMARY             	and exclusion criteria below. They will not receive metformin and will not
TR:TREATMENT_SUMMARY             	return for repeat visits after 3 months. Metformin therapy: Previous studies
TR:TREATMENT_SUMMARY             	with metformin demonstrated improvement in insulin sensitivity as early as 3
TR:TREATMENT_SUMMARY             	months with 1000 mg daily.(5, 33, 34) Metformin will be initiated with 500 mg
TR:TREATMENT_SUMMARY             	extended-release tablet daily for one week, 1000 mg daily for one week and then
TR:TREATMENT_SUMMARY             	1500 mg daily. Visits 4 and 5 will be conducted three months after full dose is
TR:TREATMENT_SUMMARY             	achieved. Oral glucose tolerance test: After 2 baseline fasting samples, 75 g of
TR:TREATMENT_SUMMARY             	oral dextrose will be ingested with blood samples will be drawn at 10’, 20’,
TR:TREATMENT_SUMMARY             	30’, 60’, 90’, 120’, 150’and 180’ for measurement of glucose,
TR:TREATMENT_SUMMARY             	insulin, c-peptide. Insulin sensitivity will be calculated using the oral
TR:TREATMENT_SUMMARY             	glucose minimal model. Stable isotope tracer infusions (Figure 5): Three days
TR:TREATMENT_SUMMARY             	prior to the tracer study, the participants will be placed on a
TR:TREATMENT_SUMMARY             	weight-maintaining diet consisting of 50% carbohydrates, 20% protein, and 30%
TR:TREATMENT_SUMMARY             	fats. Fat free mass (FFM) measured by dual-energy x-ray absorptiometry will be
TR:TREATMENT_SUMMARY             	used for dose calculations of the stable isotope tracers and insulin infusions
TR:TREATMENT_SUMMARY             	for the hyperinsulinemic-euglycemic clamp. A priming bolus dose of
TR:TREATMENT_SUMMARY             	L-[α-15N]-lysine, 3 to 5 μmol/kg FFM, will be given at the start of a 3 hour
TR:TREATMENT_SUMMARY             	infusion of 3 to 5 μmol/kg FFM/hr to achieve a plateau as previously
TR:TREATMENT_SUMMARY             	described.(29) At the same time, a priming bolus of 1 to 2 μmol/kg FFM
TR:TREATMENT_SUMMARY             	L-[1-13C]-2-aminoadipic acid will be given followed by infusion of 1 to 2
TR:TREATMENT_SUMMARY             	μmol/kg/hr based on prior study.(30) A retrograde hand intravenous line will be
TR:TREATMENT_SUMMARY             	placed with the hand placed in a warm box maintained at 140°F to obtain
TR:TREATMENT_SUMMARY             	arterialized venous blood samples for measurement of lysine and AAA
TR:TREATMENT_SUMMARY             	concentrations and stable isotopic enrichment at steady state and during the
TR:TREATMENT_SUMMARY             	clamp. Hyperinsulinemic-euglycemic clamp: We will perform a
TR:TREATMENT_SUMMARY             	hyperinsulinemic-euglycemic clamp as previously described except that in this
TR:TREATMENT_SUMMARY             	current proposal we will perform the study for 3 hours.(36) The goal for this
TR:TREATMENT_SUMMARY             	infusion is to assess the effect of hyperinsulinemia on lysine and AAA kinetics
TR:TREATMENT_SUMMARY             	and whether metformin changes the effect of hyperinsulinemia. We will collect
TR:TREATMENT_SUMMARY             	samples every 10 min for glucose. 40% dextrose will be infused at a variable
TR:TREATMENT_SUMMARY             	rate during the clamp to maintain euglycemia.(36) During the last hour of the
TR:TREATMENT_SUMMARY             	clamp, 5 blood samples will be drawn for measurement of stable isotope tracer
TR:TREATMENT_SUMMARY             	enrichment and amino acid concentrations.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Plasma lysine and AAA concentrations and isotopic enrichment will be analyzed as
SP:SAMPLEPREP_SUMMARY            	previous described via a Thermo Fisher Q Exactive plus mass spectrometer coupled
SP:SAMPLEPREP_SUMMARY            	with a Dionex UltiMate 3000 Binary RSLC liquid chromatograph.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
MS:INSTRUMENT_NAME               	Thermo Q Exactive Plus Orbitrap
CH:COLUMN_NAME                   	Zorbax Extended C18
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Thermo Q Exactive Plus Orbitrap
MS:INSTRUMENT_TYPE               	Orbitrap
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	MPE (molar percent excess )
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	MPE
MS_METABOLITE_DATA_START
Samples	ms6032-1	ms6032-2	ms6032-3	ms6032-4	ms6032-5	ms6032-6	ms6032-7	ms6032-8	ms6032-9	ms6032-10	ms6032-11	ms6039-1	ms6039-2	ms6039-3	ms6039-4	ms6039-5	ms6039-6	ms6039-7	ms6039-8	ms6039-9	ms6039-10	ms6039-11	ms6087-1	ms6087-2	ms6087-3	ms6087-4	ms6087-5	ms6087-6	ms6087-7	ms6087-8	ms6087-9	ms6087-10	ms6087-11	ms6184-1	ms6184-2	ms6184-3	ms6184-4	ms6184-5	ms6184-6	ms6184-7	ms6184-8	ms6184-9	ms6184-10	ms6184-11	ms6185-1	ms6185-2	ms6185-3	ms6185-4	ms6185-5	ms6185-6	ms6185-7	ms6185-8	ms6185-9	ms6185-10	ms6185-11	ms6189-1	ms6189-2	ms6189-3	ms6189-4	ms6189-5	ms6189-6	ms6189-7	ms6189-8	ms6189-9	ms6189-10	ms6189-11	ms6188-1	ms6188-2	ms6188-3	ms6188-4	ms6188-5	ms6188-6	ms6188-7	ms6188-8	ms6188-9	ms6188-10	ms6188-11	ms6243-1	ms6243-2	ms6243-3	ms6243-4	ms6243-5	ms6243-6	ms6243-7	ms6243-8	ms6243-9	ms6243-10	ms6243-11	ms6275-1	ms6275-2	ms6275-3	ms6275-4	ms6275-5	ms6275-6	ms6275-7	ms6275-8	ms6275-9	ms6275-10	ms6275-11	ms6183-1	ms6183-2	ms6183-3	ms6183-4	ms6183-5	ms6183-6	ms6183-7	ms6183-8	ms6183-9	ms6183-10	ms6183-11	ms6186-1	ms6186-2	ms6186-3	ms6186-4	ms6186-5	ms6186-6	ms6186-7	ms6186-8	ms6186-9	ms6186-10	ms6186-11	ms6187-1	ms6187-2	ms6187-3	ms6187-4	ms6187-5	ms6187-6	ms6187-7	ms6187-8	ms6187-9	ms6187-10	ms6187-11	ms6100-1	ms6100-2	ms6100-3	ms6100-4	ms6100-5	ms6100-6	ms6100-7	ms6100-8	ms6100-9	ms6100-10	ms6100-11	ms6102-1	ms6102-2	ms6102-3	ms6102-4	ms6102-5	ms6102-6	ms6102-7	ms6102-8	ms6102-9	ms6102-10	ms6102-11	ms6182-1	ms6182-2	ms6182-3	ms6182-4	ms6182-5	ms6182-6	ms6182-7	ms6182-8	ms6182-9	ms6182-10	ms6182-11	ms6034-1	ms6034-2	ms6034-3	ms6034-4	ms6034-5	ms6034-6	ms6034-7	ms6034-8	ms6034-9	ms6034-10	ms6034-11	ms6091-1	ms6091-2	ms6091-3	ms6091-4	ms6091-5	ms6091-6	ms6091-7	ms6091-8	ms6091-9	ms6091-10	ms6091-11	ms6098-1	ms6098-2	ms6098-3	ms6098-4	ms6098-5	ms6098-6	ms6098-7	ms6098-8	ms6098-9	ms6098-10	ms6098-11	ms6036-1	ms6036-2	ms6036-3	ms6036-4	ms6036-5	ms6036-6	ms6036-7	ms6036-8	ms6036-9	ms6036-10	ms6036-11	ms6042-1	ms6042-2	ms6042-3	ms6042-4	ms6042-5	ms6042-6	ms6042-7	ms6042-8	ms6042-9	ms6042-10	ms6042-11	ms6099-1	ms6099-2	ms6099-3	ms6099-4	ms6099-5	ms6099-6	ms6099-7	ms6099-8	ms6099-9	ms6099-10	ms6099-11	ms6035-1	ms6035-2	ms6035-3	ms6035-4	ms6035-5	ms6035-6	ms6035-7	ms6035-8	ms6035-9	ms6035-10	ms6035-11	ms6038-1	ms6038-2	ms6038-3	ms6038-4	ms6038-5	ms6038-6	ms6038-7	ms6038-8	ms6038-9	ms6038-10	ms6038-11	ms6101-1	ms6101-2	ms6101-3	ms6101-4	ms6101-5	ms6101-6	ms6101-7	ms6101-8	ms6101-9	ms6101-10	ms6101-11
Factors	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:control	Time point:-60 | Group:control	Time point:-45 | Group:control	Time point:-30 | Group:control	Time point:-15 | Group:control	Time point:60 | Group:control	Time point:120 | Group:control	Time point:135 | Group:control	Time point:150 | Group:control	Time point:165 | Group:control	Time point:180 | Group:control	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS	Time point:baseline | Group:PCOS	Time point:-60 | Group:PCOS	Time point:-45 | Group:PCOS	Time point:-30 | Group:PCOS	Time point:-15 | Group:PCOS	Time point:60 | Group:PCOS	Time point:120 | Group:PCOS	Time point:135 | Group:PCOS	Time point:150 | Group:PCOS	Time point:165 | Group:PCOS	Time point:180 | Group:PCOS
15N-Lysine	0	8.220201849	7.229573771	7.602940011	8.962472606	9.44810775	9.778627569	9.699053181	9.52407979	9.467029343	9.011277688	0	7.30138433	7.313307646	7.597865488	7.809396197	8.212260539	8.820759299	8.061960427	8.436862162	8.652603737	8.628242175	0	7.296598274	6.619968627	7.245649129	6.818600682	7.604409716	8.501031979	8.515329406	8.848057867	8.332903141	8.170552787	0	8.3531585	9.11418009	7.582376885	6.057923223	8.208897813	8.726478143	9.067554194	8.74623999	9.134312819	9.279216674	0	5.63034947	6.988845382	6.99880776	7.666631525	9.222927806	9.395830638	9.751775865	9.331631789	9.723218463	9.625883156	0	7.350876665	7.061629485	6.551406575	7.208154707	7.792064065	7.767635775	8.721073617	8.873350635	8.412707916	8.222716335	0	7.57298895	7.107043876	7.041635057	6.87893298	7.676194245	8.080716041	8.029046858	8.359104517	6.454746941	6.710397574	0	7.760799856	7.369783925	8.131057706	8.077694446	8.210349266	9.349791324	9.307112382	9.231711475	9.271667579	9.290801555	0	7.158717602	7.573928308	7.156864102	7.101288094	7.244140909	7.669144813	8.308198728	8.062058632	7.943998251	8.064890285	0	8.858010445	7.948839964	8.590984215	9.352592827	11.10402084	10.91565352	10.40503824	9.959986218	10.47922506	11.06359872	0	5.885066564	6.332397581	5.777289099	6.095861985	6.935150557	7.373462293	7.761877081	7.246125474	7.576085514	7.499967393	0	7.463438543	7.343950902	7.481371918	7.121400237	7.717353528	8.674783414	8.687131602	9.159107707	8.857037659	9.065242743	0	7.768837463	7.601394817	8.025428077	7.805780926	7.69103455	8.753974732	8.728770255	8.947660255	9.180974112	9.538823597	0	8.870933304	9.326192512	9.162085385	9.820707316	10.32281709	10.12424655	9.877487179	10.31873929	10.61561514	10.25868167	0	11.49409375	10.51621019	11.64378457	11.98122632	11.27855221	13.08197058	12.24214291	12.01989555	11.74266055	13.13413685	0	9.377590824	8.486545228	8.107116297	8.929931181	9.459148293	10.29050312	10.09217222	10.08952923	10.47119932	10.65597936	0	6.775255326	6.893297286	6.498904683	6.512151944	8.416507263	8.62799425	8.809629223	8.832395514	9.137972596	8.502131742	0	6.718409604	6.740141019	5.885389195	5.646544371	6.748115701	7.619667923	7.811446762	8.076282445	8.232762981	8.825461256	0	9.826380399	9.922234665	9.453151269	8.952524203	9.606214398	8.695814292	9.609813169	9.822005773	10.54196702	11.29710477	0	5.892076129	6.536316909	6.440738495	6.748932148	7.135645728	7.096224363	7.523342274	7.376313997	8.64202323	7.970339416	0	7.64715038	7.747147479	7.888912891	8.073606763	8.332386037	8.595313269	8.84985582	8.209019044	8.616230712	8.412591533	0	9.690368639	8.737660398	9.786702271	9.513227995	10.89424183	10.46544495	10.45848144	10.28140529	10.21502698	7.985083848	0	6.070583575	7.155405447	7.683906004	6.636504724	7.393103571	8.978129926	8.844830948	9.300689197	9.83329522	9.047475804	0	9.495366797	8.508078223	8.696020245	9.220586721	10.31417866	9.425069887	9.821659508	10.76272069	10.38950773	10.14967918
15N-aminoadipic	0	2.485940782	2.537147011	2.344610507	2.591206481	3.182654359	4.356537127	4.264071992	4.619754208	4.653079251	4.93483324	0	2.009354846	2.133883774	2.160500568	2.223674632	3.125627834	3.509517874	3.740499062	3.725202729	3.679558995	3.73447425	0	1.69865229	1.667590365	1.937628252	1.628609223	2.129350688	2.62574888	2.754287854	2.954611096	3.161035889	3.034948762	0	2.559918335	2.446077006	2.515553302	2.209668414	2.919920243	3.53984396	3.467811163	2.93536945	3.299126713	3.108502818	0	1.275504884	1.527550655	1.682680177	1.750997382	2.804410053	3.428008589	4.44072037	4.463493389	4.204784459	4.267159395	0	1.737853801	1.940318664	1.933406849	2.104372637	2.14359811	3.315767686	3.064445531	3.146191254	3.136143087	3.48525946	0	1.584406222	2.056687577	2.68274039	3.076421164	2.614541499	2.958690262	3.610926982	3.330847627	3.994496392	4.334543112	0	2.7130512	2.55481461	2.659683509	2.728251941	3.435870421	3.42168759	4.214077154	4.129889242	4.801540665	4.573202552	0	2.091272227	2.209490044	2.321262588	2.499475356	3.077597685	3.554105637	3.436351587	3.593905676	3.577951476	3.864580954	0	2.969714466	2.806533624	3.055107244	2.853979159	3.815658069	4.650194465	4.573385993	4.871453838	4.825527681	4.753550151	0	1.611402509	1.893307403	1.718603488	2.06998577	2.646156632	3.373454819	3.10863377	3.165530918	3.454676529	3.338815734	0	2.233301455	2.374964163	2.598227237	2.471855786	3.673286216	4.265340535	4.590865032	4.401903171	4.36110809	4.930434183	0	1.899103569	2.546681464	2.392180308	2.789886472	3.613695698	4.009759192	3.988694814	4.151663821	4.243510423	4.466715459	0	2.247217478	2.443605921	2.574886907	2.483939767	3.184787142	4.06873228	3.960219823	4.2965552	4.275468694	4.4096568	0	3.538931604	4.015904179	4.2467634	4.529809097	5.086859357	5.856010147	5.909018114	6.453831091	7.368934724	6.768799345	0	2.199238989	2.367376971	2.806613071	2.252597243	2.925157057	3.905670304	4.117291725	4.345526281	4.191587707	4.318434253	0	1.619991892	1.816242021	1.701975998	1.960893097	2.58162048	2.773906552	2.684251543	2.928259756	2.910300407	3.275939071	0	1.684824106	1.946981948	1.968887705	1.783986186	2.124477261	2.77344812	2.551351296	2.806121308	3.083466981	2.759097725	0	2.348018201	2.634567884	2.731319354	2.957339437	3.590941455	4.008617121	3.879337813	4.064920566	4.470519005	4.508491859	0	1.663524799	1.777314629	1.895559971	2.018696845	2.445946205	3.619814063	3.130250359	2.934900272	3.10363312	3.048326355	0	2.277503078	2.161352096	2.61077759	2.551033311	3.224267087	3.856003974	4.233851993	4.437262859	4.300958461	4.884402868	0	2.858008479	3.306097353	3.343078388	3.280354555	3.97571651	4.909903065	4.902322314	5.064827019	4.955736516	5.253237386	0	1.417897365	1.55219946	1.574464935	1.514017739	2.361451598	2.697920743	2.795210502	2.998146394	3.159492652	3.453278666	0	2.731726397	3.495628227	3.39055208	3.30053711	3.78924635	4.704491002	5.084192988	5.239501945	5.478164581	5.580675381
13C-aminoadipic	0	12.99952826	12.59084023	11.66151593	12.09710504	14.0177734	16.63919482	16.4651847	13.88994555	14.53948355	15.19440563	0	10.38307424	11.32386906	10.45545407	10.45990972	12.95280498	13.28771577	12.72436401	12.2279767	12.3162671	12.01943641	-0.002505094	9.523997937	9.178545419	9.078011846	8.242473023	9.452627404	11.25353407	10.72597522	10.74563624	10.60295831	11.43560136	0	13.66280045	13.32202552	13.82146171	12.7727858	11.80023552	9.91778472	12.6403694	11.31722185	13.22575683	11.68618178	0	12.32623393	14.15305745	13.32930822	13.60281392	16.57464967	16.692873	18.20393294	16.36826662	16.96850242	16.11729739	0	9.713205173	8.668001375	9.23914808	8.972175518	9.284139372	11.7779481	12.35210239	12.31318266	10.43980057	11.5963235	0	11.27744505	10.61086308	10.10272099	10.16480454	12.35416007	12.21555271	13.25119045	12.1063458	9.323931206	8.649190084	0	14.97080204	11.48416407	12.83068819	11.08854212	12.77558762	14.289612	14.66709335	12.86722411	15.07060919	13.03279239	0	8.514634427	8.106128736	9.407170308	7.400122092	9.260858371	8.257767124	10.12050709	9.769574011	9.688651914	9.574588083	0	16.62769456	13.37880598	16.62464853	15.65138029	16.60023924	17.26226453	17.46917627	15.28851338	17.10336748	17.623013	0	8.500192765	9.911334928	8.429566897	9.134241399	8.771214008	11.13184943	9.284848224	10.33990435	10.31890671	9.887460958	0	10.51468623	9.719614366	10.48353175	9.91014957	10.53041767	11.8740007	12.87407572	11.04689678	13.57490759	12.42706294	0	17.011362	15.39513836	14.62837301	15.91407655	16.52857924	16.53668298	15.6044422	15.0607162	16.43741357	17.28763481	0	10.25479292	9.637813317	8.55877909	10.22442206	11.46075106	12.57230921	10.88596721	11.72074579	11.96543883	11.40823514	0	29.62479866	26.94493725	26.36220322	27.44162328	23.67226922	28.26208209	28.32793098	22.77404067	28.74881453	27.34314539	0	17.61391283	14.55907471	12.55742012	14.36550671	14.40971898	14.96568073	15.11384304	15.6922992	14.86130679	14.26410264	0	7.591701894	7.901028803	6.873877379	8.48472351	10.60416626	10.42864055	10.05606788	11.16760909	10.40643864	10.38729296	0	9.189291479	9.293427401	9.041797275	7.54329177	9.313656527	10.44072388	9.65443942	10.42850342	10.32043128	10.45561545	0	10.62919692	10.50782444	9.275937806	11.30216407	11.54563353	12.28093494	11.8988059	11.9939551	13.22244882	13.0934169	0	9.190247801	9.53352525	9.347192388	9.802214501	9.861161198	11.22221949	10.25881968	10.49537395	11.50002789	11.72481591	0	11.61269674	11.29882976	11.26624087	11.09636531	11.2662554	11.42599491	11.39501628	11.44771598	11.56012573	10.72435659	0	15.43982002	14.57026196	14.28677183	14.71645954	15.66556057	14.86265441	15.36744576	14.86841821	14.55650158	12.75491547	0	9.339598557	10.03044904	10.12262267	8.927702045	10.83659856	12.27201682	11.74527141	12.49517994	13.51699617	12.78892409	0	14.52049965	13.62225623	14.49860339	13.29134731	14.9385478	14.1505489	14.4587477	15.54191228	15.30884055	14.78003614
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
15N-Lysine
15N-aminoadipic
13C-aminoadipic
METABOLITES_END
#END